Navigating the Evolving Treatment Landscape in HER2-mutated NSCLC - Episode 12

Challenges and Unmet Needs in HER2-Mutated NSCLC

, , , ,

The expert panel shares its thoughts on current challenges and unmet needs in the overall HER2-mutated non–small cell lung cancer treatment landscape.

EP. 1: Diagnosing HER2-mutated NSCLC
EP. 2: Biomarker Testing Challenges in HER2-mutated NSCLC
EP. 3: Role of ADCs in HER2-Mutated NSCLC
EP. 4: DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC
EP. 5: The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC
EP. 6: DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC
EP. 7: Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC
EP. 8: The Potential Role of TKIs in HER2-Mutated NSCLC
EP. 9: Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC
EP. 10: First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC
EP. 11: Adverse Events Associated With TKIs in HER2-Mutated NSCLC
Now Viewing
EP. 12: Challenges and Unmet Needs in HER2-Mutated NSCLC
EP. 13: Treatment Considerations in HER2-Mutated NSCLC
EP. 14: Key Takeaways in HER2-Mutated NSCLC